Feasibility of Protocolised Analgosedation in ECMO (ECMO-SED)
Feasibility of a Cluster Randomised Control Trial Evaluating a Co-designed Analgosedation Protocol in Extracorporeal Membrane Oxygenation (ECMO) Patients
Sedation (painkillers and sedative drugs) treats pain, reduces suffering, and helps patients in the intensive care unit (ICU) receiving extracorporeal membrane oxygenation (ECMO) remain comfortable. ECMO is a life support machine that provides oxygen and removes waste gases (carbon dioxide) in very sick patients with severe heart or lung failure. About 300-400 patients per year receive ECMO in the UK. These patients are younger and generally more healthy compared to other critically ill patients. However patients that survive ECMO have long-term health problems. These include anxiety, memory problems, withdrawal from medicines, and mobility issues. These problems issues could all be related to the type and amount of sedation given.
A sedation protocol is a way of guiding healthcare professionals how much sedation is given to patients in ICU. Too much sedation can cause confusion, hallucinations, excessive sleepiness, and longer time in hospital. Too little sedation can cause pain, distress, and also a longer time in hospital. Using a sedation protocol in non-ECMO patients has been shown to reduce these complications.
However, there are no protocols for giving sedation to ECMO patients in research papers. Investigators know healthcare staff find it difficult to manage sedation, and higher amounts of sedation is given to ECMO patients.
Aims:
To see whether it is possible to run a trial that compares using a sedation protocol against usual care.
Design/methods:
Thirty to 60 ECMO patients will be chosen and will be put into one of two groups. One group will receive usual care, and the other will receive care using the sedation protocol. The investigators will collect information from both groups to find out if the study design works and how many patients agree to take part.
Patient and public involvement/engagement:
The investigators received feedback from patients and family member participants which helped to design this proposal, the lay summary and what to measure in a trial. They will advise how the investigators should review study findings, and support sharing of results to the public.
Impact/dissemination:
The investigators will share findings through social media, patient charities, research papers and conferences.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Research questions
- Is a cluster randomised controlled trial (cRCT) of a co-designed analgosedation protocol for adult ECMO patients feasible to conduct in terms of intervention delivery and data collection?
- What are the barriers and facilitators to the conduct of a cRCT of a co-designed analgosedation protocol?
STUDY AIM AND OBJECTIVES Overall aim and purpose • The overall aim is to test the feasibility of a cRCT of a co-designed analgosedation protocol for use with adult extracorporeal membrane oxygenation (ECMO) patients.
Objectives
Overall objective
• To evaluate the feasibility of a cRCT of a co-designed analgosedation protocol for ECMO patients in terms of intervention delivery and data collection. This will inform the design of a future adequately powered cRCT.
Feasibility objectives
- To assess fidelity of intervention delivery (adherence to the study protocol)
- To establish barriers and facilitators to trial conduct and intervention delivery
- To assess the feasibility of data collection methods
- To assess the acceptability of the co-designed analgosedation protocol from the perspectives of nursing, medical, and pharmacy staff using it.
Exploratory clinical objectives include
- Duration of mechanical ventilation
- Occurrence, and duration of delirium (days)
- Duration of ECMO treatment
- Daily analgosedation doses (enteral and intravenous opioids and sedatives)
- Average Pain (Critical Care Pain Observation Tool - CPOT), sedation (Richmond Agitation and Sedation Scale - RASS) and delirium (Confusion Assessment Method for the Intensive Care Unit - CAM-ICU) scores
- ICU and hospital length of stay
- ICU and hospital mortality
- Accidental removal of the endotracheal tube
- Accidental removal of other tubes and invasive lines
- Use of physical restraints
STUDY DESIGN
The investigators will conduct a feasibility cRCT in two tertiary adult ECMO centres within Guy's & St Thomas' NHS Foundation Trust (St Thomas' Hospital (cluster 1) and Royal Brompton Hospital (cluster 2)). The investigators have chosen a cRCT study design to reduce intervention contamination by healthcare professional participants delivering care in the intervention or control arms. This is important to ensure all patients within the same cluster receive the same treatment.
Study procedures
Control arm: Will comprise the standard of care for delivery of analgosedation and all other medical treatment while in the ICU. Standard of care includes use of pain (Critical-Care Pain Observation Tool - CPOT), and sedation (Richmond Agitation and Sedation Scale - RASS) scores to assess pain and sedation levels, and the use of opioids and sedatives to keep patients comfortable and pain-free with drug type and dosing selected by the ICU clinical team. One cluster (ICU) will be randomly assigned to this arm.
Intervention arm: Will comprise the use of the previously co-designed analgosedation protocol. The analgosedation protocol will focus on setting a daily target for pain using the CPOT score, and sedation using the RASS score. The protocol will include recommended opioid and sedative medicines and their dose ranges, guidance on titration of opioid and sedative doses based on pain and sedation scores, daily interruption of sedation, use of non-pharmacological approaches to keep patients calm and to promote sleep, and methods of weaning opioids and sedatives. Patients will also be assessed daily for delirium using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). All other treatments will be as per standard care and at the discretion of the treating clinical team. The sedation protocol will be used for up to 10 days after commencement of ECMO. One cluster (ICU) will be randomly assigned to this arm.
Randomisation and blinding
The ECMO unit will be the unit of randomisation, with patients allocated to treatment or control according to their assigned cluster. Participants will be included if they meet the inclusion criteria. Randomisation will be performed via the Sealed Envelope online randomisation module following ethics approval to provide enough time to organise staff training on the use of the protocol. Each cluster will be informed ahead of time as to which arm they will be allocated to for the purposes of training on the protocol. Given the nature of the intervention, neither the treating clinicians, patients, nor data collectors can be blinded. However, exploratory outcome measures are objective and documented in the patient's medical record.
Staff training on the use of the protocol
Healthcare professionals (doctors, nurses and pharmacists) will receive training from the research team on the use of the protocol prior to the study launching and during trial recruitment in the centre allocated to the intervention arm. The investigators will provide training (in-person and virtually) on elements of the trial protocol, including analgosedation dose titration, targeted Richmond Agitation and Sedation Scale (RASS) scores, and the duration of protocol use. The investigators will also provide refresher training to staff in both arms of the study on the use of CPOT, RASS, and CAM-ICU assessments. A training log will be used to determine who has been trained and the date of training.
Success criteria
The investigators will assess the following criteria to inform progression to seeking funding for a future cRCT.
Progression criteria
- Adherence to the protocol as intended.
- Acceptability of the protocol by staff delivering the intervention.
The investigators will use a traffic light system to guide progression criteria as recommended in best practice guidelines.
Green: Progress to apply for trial funding, with review of screening logs and protocol revision to address any barriers to recruitment and delivery of the intervention.
Amber: Consider progression to apply for trial funding with consultation with key stakeholders, review of screening logs, and protocol revision to address any barriers to recruitment, delivery of the intervention and harness facilitators.
Red: Unable to progress to trial funding application.
Assessment of protocol adherence
The investigators will assess protocol adherence daily using a fidelity checklist. Adherence to the protocol will be deemed good if 70% of daily fidelity checklist items have been met over the study period.
- Daily RASS target recorded in electronic health record
- RASS score recorded in electronic health record at least once per 12-hour nursing shift
- CPOT behavioural pain score recorded in electronic health record at least once per 12-hour nursing shift
- Delirium screen (CAM-ICU) recorded in electronic health record if RASS >-3
- Fentanyl used as continuous opioid infusion
- Fentanyl continuous infusion dose within recommended range over the 24 hours
- Propofol and/or midazolam used as continuous infusion sedative
- Propofol and/or midazolam continuous infusion dose within recommended range over the 24 hours
Assessment of acceptability of the protocol
Staff participants will complete the validated Acceptability of Intervention Measure (AIM)/Feasibility of Intervention Measure (FIM) questionnaires and will be offered the opportunity to participate in an interview. The questionnaire will include questions including whether the analgosedation protocol meets staff approval and is appealing for ECMO patients, and if it is liked and welcomed for use in clinical practice. The AIM/FIM questionnaire will be administered daily to staff, who have used the protocol, before they go home after their day or night shift. The investigators will use codes to track if staff have answered the AIM questionnaire more than once during the study period. The analgosedation protocol will be deemed acceptable if all participants rated the acceptability questions as a mark of 4 (agree) or 5 (completely agree) in 70% of cases across all completed questionnaires.
Fidelity
The investigators will use the Theoretical Domains Framework (TDF) to guide both the measurement of fidelity and to understand factors affecting trial delivery. The progression criteria for protocol adherence are based on at least a 70% fidelity rate in line with a previous study.
Data to be collected
Feasibility and fidelity trial data
The direct care team will enter de-identified data on to the electronic case report form (e-CRF). The investigators will develop an e-CRF to collect de-identified patient demographic characteristics, analgosedation management and patient outcomes in the intervention and control arms. The investigators will develop an additional e-CRF to allow the collection of feasibility data (assessment of protocol adherence). The research team will enter de-identified data to the electronic data capture system (REDCap). This is to ensure participant confidentiality. The investigators will ensure a delegation log is completed.
Data collected will include baseline characteristics and severity scores (age, gender, height, weight, body mass index, worst documented PaO2/FiO2 (P/F) ratio prior to ECMO cannulation, APACHE II scores, admission SOFA scores, admission C-reactive protein, pregnancy or postpartum, ECMO modality, primary reason for ECMO, admission type, past medical history), and exploratory clinical objectives from the patient's medical notes. The research team will record all patients who were enrolled into the study using a Site Master Log sheet and Screening Log, and record any concerns relating to the intervention. The investigators will collect sedation data up to 10 days for the intervention and control arms.
The investigators will collect data on intervention fidelity at the site using the sedation protocol using the fidelity checklist.
The investigators will conduct semi-structured interviews online via Microsoft Teams with staff participants to explore their perceptions of barriers and facilitators to use of the co-designed sedation protocol and their views on its acceptability during the feasibility trial. The investigators will use a interview guide and a questionnaire, which will be based on the TDF and the AIM/FIM Questionnaire. The investigators will use purposive sampling (based on years of ICU experience and the number of patient participants they have managed using the protocol) to interview doctors, nurses, and pharmacists involved in protocol delivery. The investigators will collect basic demographic characteristics, professional role, years of ICU experience. All interviews will be digitally recorded and transcribed by a professional transcription company.
Data analysis
Quantitative analysis
Fidelity analysis
The investigators will sum the scores of the daily checklist to a maximum score of 8 (if an item on the checklist is ticked yes, a score of 1 is added). The investigators will average the scores of all the daily checklists completed per patient during study enrolment. Protocol adherence will be defined as at least 70% of the daily checklist score.
Acceptability questionnaire analysis
The investigators will review all completed AIM/FIM questionnaires and if at least 70% of responses are recorded as 4 (agree) or 5 (completely agree), acceptability will be achieved.
Exploratory patient outcomes
The investigators will calculate the mean (standard deviation) and median (interquartile range) of duration of mechanical ventilation, occurrence and duration of delirium, duration of ECMO, daily (24-hour period) dose of each analgosedation drug, ICU and hospital length of stay, and ICU and hospital mortality. The investigators will also calculate counts (%) for occurrence of delirium, accidental removal of the endotracheal tube, accidental removal of other tubes and invasive lines, and use of physical restraints. The investigators will convert all opioids (enteral and intravenous) to morphine dose equivalents; benzodiazepines (enteral and intravenous) into midazolam dose equivalents using opioid and benzodiazepine conversion tables (47,48). The investigators will calculate daily doses by dividing the sum of all analgosedation doses received during the data collection period by the number of days of collected data. Data will be analysed using R Studio.
Qualitative analysis
To analyse data on barriers, facilitators and acceptability, the investigators will use the Framework Method informed by the AIM/FIM Questionnaire and Theoretical Domains Framework (TDF). The investigators will dual-code transcripts coding data within the domains of the TFA and the TDF. The investigators will group and mark codes from the transcripts with one or more short descriptors to organise the raw data. The codes will then be grouped, summarised and categorised within the framework. The investigators will use NVIVO to support the coding and the analysis of the qualitative data.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Christopher Remmington, MPharm
- Número de telefone: +442078365454
- E-mail: christopher.remmington@nhs.net
Estude backup de contato
- Nome: Louise Rose, PhD
- Número de telefone: +4478365454
- E-mail: louise.rose@kcl.ac.uk
Locais de estudo
-
-
-
London, Reino Unido, SE1 7EH
- Guy's and St Thomas' NHS Foundation Trust
-
Contato:
- Gillian Radcliffe
- Número de telefone: +447966 123385
- E-mail: Gill.Radcliffe@nhs.net
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Aged 18 years and older
- Receiving IV continuous infusions of analgosedation medication
- Receiving ECMO treatment
Exclusion Criteria:
- There will be no exclusion criteria as analgosedation management is routine for all adult ECMO patients.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Outro: Intervention arm - use of sedation protocol
The analgosedation protocol will focus on setting a daily target for pain using the CPOT score, and sedation using the RASS score.
The protocol will include recommended opioid and sedative medicines and their dose ranges, guidance on titration of opioid and sedative doses based on pain and sedation scores, daily interruption of sedation, use of non-pharmacological approaches to keep patients calm and to promote sleep, and methods of weaning opioids and sedatives.
Patients will also be assessed daily for delirium using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU).
All other treatments will be as per standard care and at the discretion of the treating clinical team.
The sedation protocol will be used for up to 10 days after commencement of ECMO.
One cluster (ICU) will be randomly assigned to this arm.
|
Will comprise the use of the previously co-designed analgosedation protocol.
The analgosedation protocol will focus on setting a daily target for pain using the CPOT score, and sedation using the RASS score.
The protocol will include recommended opioid and sedative medicines and their dose ranges, guidance on titration of opioid and sedative doses based on pain and sedation scores, daily interruption of sedation, use of non-pharmacological approaches to keep patients calm and to promote sleep, and methods of weaning opioids and sedatives.
Patients will also be assessed daily for delirium using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU).
All other treatments will be as per standard care and at the discretion of the treating clinical team.
The sedation protocol will be used for up to 10 days after commencement of ECMO.
One cluster (ICU) will be randomly assigned to this arm.
Outros nomes:
|
|
Sem intervenção: Standard of care for delivery of analgosedation and all other medical treatment while in the ICU
Will comprise the standard of care for delivery of analgosedation and all other medical treatment while in the ICU.
Standard of care includes use of pain (Critical-Care Pain Observation Tool - CPOT), and sedation (Richmond Agitation and Sedation Scale - RASS) scores to assess pain and sedation levels, and the use of opioids and sedatives to keep patients comfortable and pain-free with drug type and dosing selected by the ICU clinical team.
One cluster (ICU) will be randomly assigned to this arm.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Feasibility of protocolised sedation
Prazo: From date of randomisation to the end of treatment at 10 days, assessed up to 10 days
|
Ability to;
|
From date of randomisation to the end of treatment at 10 days, assessed up to 10 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Duration of mechanical ventilation
Prazo: Defined as date of randomisation until first successful unassisted breathing (no inspiratory support for 48hrs or ECMO) or death or hospital discharge (at recruiting site), assessed up to 30 days. Censor at hospital discharge in recruiting centre.
|
Defined as time from randomisation until first successful unassisted breathing (no inspiratory support for 48hrs or ECMO) or death or hospital discharge (at recruiting site).
Mean or median time in hours.
|
Defined as date of randomisation until first successful unassisted breathing (no inspiratory support for 48hrs or ECMO) or death or hospital discharge (at recruiting site), assessed up to 30 days. Censor at hospital discharge in recruiting centre.
|
|
Occurrence and duration of delirium
Prazo: From date of randomisation to 10 days or death or transfer if occurs first, assessed up to 10 days.
|
Occurrence and duration of delirium
|
From date of randomisation to 10 days or death or transfer if occurs first, assessed up to 10 days.
|
|
Duration of ECMO treatment
Prazo: From date of randomisation to ECMO decannulation, assessed up 30 days.
|
Number of days of ECMO treatment from start date to finish date of ECMO
|
From date of randomisation to ECMO decannulation, assessed up 30 days.
|
|
Daily morphine equivalent doses
Prazo: From date of randomisation to 10 days or death/transfer if occurs first, assessed up to 10 days.
|
Total doses of enteral and intravenous opioids
|
From date of randomisation to 10 days or death/transfer if occurs first, assessed up to 10 days.
|
|
Daily midazolam equivalent doses
Prazo: From date of randomisation to 10 days or death/transfer if occurs first, assessed up to 10 days.
|
Total enteral and intravenous benzodiazepine doses
|
From date of randomisation to 10 days or death/transfer if occurs first, assessed up to 10 days.
|
|
Daily propofol doses
Prazo: From date of randomisation to 10 days or death/transfer if if occurs first, assessed up to 10 days.
|
Total propofol doses
|
From date of randomisation to 10 days or death/transfer if if occurs first, assessed up to 10 days.
|
|
ICU length of stay
Prazo: From date of randomisation to end of stay in ICU in recruiting centre, assessed up to 30 days.
|
Duration of stay in ICU (days) in recruiting centre
|
From date of randomisation to end of stay in ICU in recruiting centre, assessed up to 30 days.
|
|
Hospital length of stay
Prazo: From date of randomisation to end of stay in hospital in recruiting centre, assessed up to 30 days.
|
Duration of stay in hospital (days) in recruiting centre
|
From date of randomisation to end of stay in hospital in recruiting centre, assessed up to 30 days.
|
|
ICU mortality
Prazo: From date of randomisation to death in ICU in recruiting centre, assessed up to 30 days.
|
Death in ICU in recruiting centre
|
From date of randomisation to death in ICU in recruiting centre, assessed up to 30 days.
|
|
Hospital mortality
Prazo: From date of randomisation to death in hospital in recruiting centre, assessed up to 30 days.
|
Death in hospital of recruiting centre
|
From date of randomisation to death in hospital in recruiting centre, assessed up to 30 days.
|
|
Accidental removal of the endotracheal tube
Prazo: From date of randomisation to 10 days or death or transfer if occurs first, assessed up to 10 days.
|
Removal of endotracheal tube by patient during protocolised sedation
|
From date of randomisation to 10 days or death or transfer if occurs first, assessed up to 10 days.
|
|
Accidental removal of other tubes and invasive lines
Prazo: From date of randomisation to 10 days or death or transfer if occurs first, assessed up to 10 days.
|
Removal of other tubes and invasive lines by patient during protocolised sedation
|
From date of randomisation to 10 days or death or transfer if occurs first, assessed up to 10 days.
|
|
Use of physical restraints
Prazo: From randomisation to 10 days or death or transfer if occurs first, assessed up to 10 days.
|
Use of physical restraints during protocolised sedation
|
From randomisation to 10 days or death or transfer if occurs first, assessed up to 10 days.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Cadeira de estudo: Louise Rose, PhD, King's College London
Publicações e links úteis
Publicações Gerais
- Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE Jr, Inouye SK, Bernard GR, Dittus RS. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004 Apr 14;291(14):1753-62. doi: 10.1001/jama.291.14.1753.
- Devlin JW, Skrobik Y, Gelinas C, Needham DM, Slooter AJC, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochwerg B, Balas MC, van den Boogaard M, Bosma KJ, Brummel NE, Chanques G, Denehy L, Drouot X, Fraser GL, Harris JE, Joffe AM, Kho ME, Kress JP, Lanphere JA, McKinley S, Neufeld KJ, Pisani MA, Payen JF, Pun BT, Puntillo KA, Riker RR, Robinson BRH, Shehabi Y, Szumita PM, Winkelman C, Centofanti JE, Price C, Nikayin S, Misak CJ, Flood PD, Kiedrowski K, Alhazzani W. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018 Sep;46(9):e825-e873. doi: 10.1097/CCM.0000000000003299.
- Brook AD, Ahrens TS, Schaiff R, Prentice D, Sherman G, Shannon W, Kollef MH. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med. 1999 Dec;27(12):2609-15. doi: 10.1097/00003246-199912000-00001.
- Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000 May 18;342(20):1471-7. doi: 10.1056/NEJM200005183422002.
- Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters SJ. Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study. Trials. 2014 Jul 3;15:264. doi: 10.1186/1745-6215-15-264.
- Balzer F, Weiss B, Kumpf O, Treskatsch S, Spies C, Wernecke KD, Krannich A, Kastrup M. Early deep sedation is associated with decreased in-hospital and two-year follow-up survival. Crit Care. 2015 Apr 28;19(1):197. doi: 10.1186/s13054-015-0929-2.
- Sim J, Dawson A. Informed consent and cluster-randomized trials. Am J Public Health. 2012 Mar;102(3):480-5. doi: 10.2105/AJPH.2011.300389. Epub 2012 Jan 19.
- Brodie D, Bacchetta M. Extracorporeal membrane oxygenation for ARDS in adults. N Engl J Med. 2011 Nov 17;365(20):1905-14. doi: 10.1056/NEJMct1103720.
- Cane J, O'Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci. 2012 Apr 24;7:37. doi: 10.1186/1748-5908-7-37.
- Shekar K, Fraser JF, Smith MT, Roberts JA. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care. 2012 Dec;27(6):741.e9-18. doi: 10.1016/j.jcrc.2012.02.013. Epub 2012 Apr 18.
- Weijer C, Grimshaw JM, Eccles MP, McRae AD, White A, Brehaut JC, Taljaard M; Ottawa Ethics of Cluster Randomized Trials Consensus Group. The Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials. PLoS Med. 2012;9(11):e1001346. doi: 10.1371/journal.pmed.1001346. Epub 2012 Nov 20.
- Grap MJ, Munro CL, Wetzel PA, Best AM, Ketchum JM, Hamilton VA, Arief NY, Pickler R, Sessler CN. Sedation in adults receiving mechanical ventilation: physiological and comfort outcomes. Am J Crit Care. 2012 May;21(3):e53-63; quiz e64. doi: 10.4037/ajcc2012301.
- deBacker J, Tamberg E, Munshi L, Burry L, Fan E, Mehta S. Sedation Practice in Extracorporeal Membrane Oxygenation-Treated Patients with Acute Respiratory Distress Syndrome: A Retrospective Study. ASAIO J. 2018 Jul/Aug;64(4):544-551. doi: 10.1097/MAT.0000000000000658.
- Salluh JI, Soares M, Teles JM, Ceraso D, Raimondi N, Nava VS, Blasquez P, Ugarte S, Ibanez-Guzman C, Centeno JV, Laca M, Grecco G, Jimenez E, Arias-Rivera S, Duenas C, Rocha MG; Delirium Epidemiology in Critical Care Study Group. Delirium epidemiology in critical care (DECCA): an international study. Crit Care. 2010;14(6):R210. doi: 10.1186/cc9333. Epub 2010 Nov 23.
- Rose L, Fitzgerald E, Cook D, Kim S, Steinberg M, Devlin JW, Ashley BJ, Dodek P, Smith O, Poretta K, Lee Y, Burns K, Harvey J, Skrobik Y, Fergusson D, Meade M, Kraguljac A, Burry L, Mehta S; SLEAP Investigators; Canadian Critical Care Trials Group. Clinician perspectives on protocols designed to minimize sedation. J Crit Care. 2015 Apr;30(2):348-52. doi: 10.1016/j.jcrc.2014.10.021. Epub 2014 Oct 30.
- Rose RL, Bucknall T. Staff perceptions on the use of a sedation protocol in the intensive care setting. Aust Crit Care. 2004 Nov;17(4):151-9. doi: 10.1016/s1036-7314(04)80020-1.
- Shehabi Y, Bellomo R, Kadiman S, Ti LK, Howe B, Reade MC, Khoo TM, Alias A, Wong YL, Mukhopadhyay A, McArthur C, Seppelt I, Webb SA, Green M, Bailey MJ; Sedation Practice in Intensive Care Evaluation (SPICE) Study Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Sedation Intensity in the First 48 Hours of Mechanical Ventilation and 180-Day Mortality: A Multinational Prospective Longitudinal Cohort Study. Crit Care Med. 2018 Jun;46(6):850-859. doi: 10.1097/CCM.0000000000003071.
- Remmington C, McKenzie C, Camporota L, Hanks F, Barker M, Sanderson B, Rose L. Analgosedation in extracorporeal membrane oxygenation: a retrospective UK cohort study. Br J Anaesth. 2023 Aug;131(2):e50-e52. doi: 10.1016/j.bja.2023.05.011. Epub 2023 Jun 19. No abstract available.
- Kamdar BB, Combs MP, Colantuoni E, King LM, Niessen T, Neufeld KJ, Collop NA, Needham DM. The association of sleep quality, delirium, and sedation status with daily participation in physical therapy in the ICU. Crit Care. 2016 Aug 18;19:261. doi: 10.1186/s13054-016-1433-z.
- Dzierba AL, Abrams D, Brodie D. Medicating patients during extracorporeal membrane oxygenation: the evidence is building. Crit Care. 2017 Mar 21;21(1):66. doi: 10.1186/s13054-017-1644-y.
- Marhong JD, DeBacker J, Viau-Lapointe J, Munshi L, Del Sorbo L, Burry L, Fan E, Mehta S. Sedation and Mobilization During Venovenous Extracorporeal Membrane Oxygenation for Acute Respiratory Failure: An International Survey. Crit Care Med. 2017 Nov;45(11):1893-1899. doi: 10.1097/CCM.0000000000002702.
- Dzierba AL, Abrams D, Madahar P, Muir J, Agerstrand C, Brodie D. Current practice and perceptions regarding pain, agitation and delirium management in patients receiving venovenous extracorporeal membrane oxygenation. J Crit Care. 2019 Oct;53:98-106. doi: 10.1016/j.jcrc.2019.05.014. Epub 2019 May 29.
- Blackwood B, Tume LN, Morris KP, Clarke M, McDowell C, Hemming K, Peters MJ, McIlmurray L, Jordan J, Agus A, Murray M, Parslow R, Walsh TS, Macrae D, Easter C, Feltbower RG, McAuley DF; SANDWICH Collaborators. Effect of a Sedation and Ventilator Liberation Protocol vs Usual Care on Duration of Invasive Mechanical Ventilation in Pediatric Intensive Care Units: A Randomized Clinical Trial. JAMA. 2021 Aug 3;326(5):401-410. doi: 10.1001/jama.2021.10296.
- Blackwood B, Agus A, Boyle R, Clarke M, Hemming K, Jordan J, Macrae D, McAuley DF, McDowell C, McIlmurray L, Morris KP, Murray M, Parslow R, Peters MJ, Tume LN, Walsh T; Paediatric Intensive Care Society Study Group (PICS-SG). Sedation AND Weaning In Children (SANDWICH): protocol for a cluster randomised stepped wedge trial. BMJ Open. 2019 Nov 10;9(11):e031630. doi: 10.1136/bmjopen-2019-031630.
- Nix HP, Weijer C, Brehaut JC, Forster D, Goldstein CE, Taljaard M. Informed consent in cluster randomised trials: a guide for the perplexed. BMJ Open. 2021 Sep 27;11(9):e054213. doi: 10.1136/bmjopen-2021-054213.
- Mahmoud L, Zullo AR, Thompson BB, Wendell LC. Outcomes of protocolised analgesia and sedation in a neurocritical care unit. Brain Inj. 2018;32(7):941-947. doi: 10.1080/02699052.2018.1469167. Epub 2018 Apr 30.
- Stephens RJ, Dettmer MR, Roberts BW, Ablordeppey E, Fowler SA, Kollef MH, Fuller BM. Practice Patterns and Outcomes Associated With Early Sedation Depth in Mechanically Ventilated Patients: A Systematic Review and Meta-Analysis. Crit Care Med. 2018 Mar;46(3):471-479. doi: 10.1097/CCM.0000000000002885.
- Tompkins DA, Campbell CM. Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon? Curr Pain Headache Rep. 2011 Apr;15(2):129-36. doi: 10.1007/s11916-010-0171-1.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Manifestações Neurológicas
- Doenças do Sistema Nervoso
- Doenças Vasculares
- Doenças cardiovasculares
- Processos Patológicos
- Doenças cardíacas
- Doenças Respiratórias
- Manifestações Neurocomportamentais
- Doenças pulmonares
- Distúrbios Respiratórios
- Infarte
- Necrose
- Isquemia do miocárdio
- Infarto do miocárdio
- Isquemia
- Choque
- Distúrbios Perceptivos
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Síndrome do Desconforto Respiratório
- Choque, Cardiogênico
- Agnosia
Outros números de identificação do estudo
- IRAS number: 354798
- NIHR304092 (Número de outro subsídio/financiamento: National Institute for Health and Care Research)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .